Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

HUS, Finland Clinical Trials

A listing of HUS, Finland clinical trials actively recruiting patients volunteers.

Found (189) clinical trials

The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients

Background: Globally, 15% of the population is affected by migraines at some point in their life-time. Pprophylactic treatment of migraines is an important part of the total management of migraine patients, having twofold goals: i) to reduce the frequency, painfulness, and/or duration of migraines, and ii) to increase the effectiveness …

Phase N/A

8.34 miles

Learn More »

Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines

Many Salmonella spp causing gastroenteritis share O antigen serotypes with Salmonella enteritidis subsp. enterica serovar Typhi (S.typhi) and could therefore be in 'reach' of the protective efficacy of the oral live typhoid fever vaccine Vivotif. Some of these Salmonellae are common causes of diarrhoea in travellers (0-30% of travellers diarrhea …

Phase

8.34 miles

Learn More »

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studyng safety and immunogenicity of a meningococcal pentavalent vaccine.

Phase

8.34 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants

This pivotal Phase 3 study will determine if MEDI8897 will prevent medically attended RSV-confirmed lower respiratory tract infections (LRTI) in healthy infants entering their first RSV season. The population to be enrolled is healthy late preterm and term infants born 35 weeks 0 days or greater gestational age (GA) who …

Phase

8.34 miles

Learn More »

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Healthy infants and toddlers will receive MenACYW conjugate vaccine or a licensed meningococcal vaccine, and routine pediatric vaccines. All participants will be assessed for immunogenicity before and after vaccination. Safety will be assessed throughout the study period, and includes solicited injection site and systemic reactions as well as unsolicited adverse …

Phase

8.34 miles

Learn More »

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in Europeans Toddlers

Study duration per participant will be approximately 30 days including: 1 day of screening and vaccination, a phone call and a safety-follow up/end of study visit at Day 8 and Day 30 after vaccine administration, respectively. Safety assessment includes solicited reactions within 7 days after vaccination, unsolicited adverse events (AEs) …

Phase

8.34 miles

Learn More »

Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Study to assess the long term safety and tolerability of ACT-541468 in adult and elderly subjects suffering from difficulties to sleep

Phase

8.45 miles

Learn More »

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab. This study will also evaluate the safety and tolerability of budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination …

Phase

8.53 miles

Learn More »

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

This study is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary anti-tumor activity of INCMGA00012 administered IV every 2, 3, or 4 weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors. In the initial …

Phase

8.53 miles

Learn More »

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

Phase

8.53 miles

Learn More »